William Samuel David, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electromyography | 16 | 2017 | 1391 | 1.850 |
Why?
|
| Botulism | 2 | 2015 | 22 | 1.030 |
Why?
|
| Amyotrophic Lateral Sclerosis | 16 | 2021 | 1421 | 0.970 |
Why?
|
| Ulnar Neuropathies | 2 | 2012 | 33 | 0.780 |
Why?
|
| Neurophysiology | 1 | 2019 | 142 | 0.620 |
Why?
|
| Nerve Compression Syndromes | 1 | 2019 | 161 | 0.600 |
Why?
|
| Myasthenia Gravis | 4 | 2021 | 201 | 0.590 |
Why?
|
| Spinal Nerve Roots | 1 | 2017 | 124 | 0.590 |
Why?
|
| Dyspnea | 2 | 2015 | 1298 | 0.590 |
Why?
|
| Cystinosis | 3 | 2022 | 25 | 0.570 |
Why?
|
| Neuromuscular Diseases | 3 | 2015 | 253 | 0.560 |
Why?
|
| Muscle Weakness | 9 | 2019 | 414 | 0.540 |
Why?
|
| Muscle, Skeletal | 12 | 2019 | 4933 | 0.530 |
Why?
|
| Neuralgia | 2 | 2019 | 568 | 0.510 |
Why?
|
| Motor Neurons | 5 | 2021 | 851 | 0.500 |
Why?
|
| Peripheral Nervous System Diseases | 5 | 2019 | 700 | 0.480 |
Why?
|
| Lower Extremity | 2 | 2019 | 1151 | 0.440 |
Why?
|
| Muscular Diseases | 5 | 2020 | 557 | 0.430 |
Why?
|
| Myositis, Inclusion Body | 3 | 2021 | 147 | 0.430 |
Why?
|
| Ganglion Cysts | 1 | 2012 | 28 | 0.430 |
Why?
|
| Mononeuropathies | 1 | 2012 | 16 | 0.430 |
Why?
|
| Wrist | 2 | 2019 | 225 | 0.420 |
Why?
|
| Rhabdomyolysis | 1 | 2012 | 150 | 0.380 |
Why?
|
| Quadriceps Muscle | 1 | 2012 | 144 | 0.380 |
Why?
|
| Myography | 3 | 2018 | 109 | 0.360 |
Why?
|
| Simvastatin | 1 | 2012 | 360 | 0.340 |
Why?
|
| Polyneuropathies | 4 | 2022 | 139 | 0.340 |
Why?
|
| Electric Stimulation | 3 | 2011 | 1770 | 0.330 |
Why?
|
| Spastic Paraplegia, Hereditary | 2 | 2009 | 157 | 0.330 |
Why?
|
| Neurology | 4 | 2022 | 762 | 0.320 |
Why?
|
| Deglutition Disorders | 4 | 2022 | 604 | 0.320 |
Why?
|
| Evoked Potentials, Motor | 4 | 2018 | 456 | 0.300 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 1377 | 0.300 |
Why?
|
| Neural Conduction | 5 | 2019 | 468 | 0.300 |
Why?
|
| Hereditary Sensory and Autonomic Neuropathies | 2 | 2019 | 40 | 0.290 |
Why?
|
| Hypesthesia | 2 | 2017 | 110 | 0.290 |
Why?
|
| Electric Impedance | 3 | 2018 | 727 | 0.290 |
Why?
|
| Superoxide Dismutase | 1 | 2009 | 596 | 0.290 |
Why?
|
| Diagnosis, Differential | 11 | 2019 | 12958 | 0.280 |
Why?
|
| Vocal Cord Paralysis | 1 | 2009 | 267 | 0.270 |
Why?
|
| GTP Phosphohydrolases | 1 | 2009 | 508 | 0.270 |
Why?
|
| Immunologic Factors | 3 | 2021 | 1575 | 0.260 |
Why?
|
| Facial Paralysis | 1 | 2009 | 338 | 0.260 |
Why?
|
| Adenosine Triphosphatases | 1 | 2009 | 836 | 0.260 |
Why?
|
| Diagnostic Techniques, Neurological | 2 | 2017 | 65 | 0.250 |
Why?
|
| Electrodiagnosis | 2 | 2003 | 154 | 0.250 |
Why?
|
| Status Asthmaticus | 2 | 2008 | 22 | 0.250 |
Why?
|
| Rabbits | 2 | 2010 | 4886 | 0.250 |
Why?
|
| Distal Myopathies | 2 | 2020 | 16 | 0.230 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 1 | 2023 | 46 | 0.220 |
Why?
|
| Ceftriaxone | 2 | 2014 | 168 | 0.220 |
Why?
|
| Myotonic Dystrophy | 1 | 2023 | 78 | 0.220 |
Why?
|
| Arthrogryposis | 2 | 2019 | 72 | 0.220 |
Why?
|
| Carpal Tunnel Syndrome | 2 | 2003 | 300 | 0.200 |
Why?
|
| Pain | 5 | 2022 | 4961 | 0.200 |
Why?
|
| Phenylenediamines | 1 | 2021 | 90 | 0.190 |
Why?
|
| Myoglobinuria | 1 | 2000 | 23 | 0.190 |
Why?
|
| Radiography, Abdominal | 2 | 2015 | 537 | 0.180 |
Why?
|
| Carbamates | 1 | 2021 | 195 | 0.170 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 1 | 2019 | 22 | 0.170 |
Why?
|
| Genes, cdc | 1 | 2019 | 116 | 0.170 |
Why?
|
| Tibial Nerve | 1 | 2019 | 57 | 0.170 |
Why?
|
| Lumbosacral Plexus | 1 | 2019 | 53 | 0.170 |
Why?
|
| Fasciculation | 1 | 1998 | 8 | 0.170 |
Why?
|
| Lipodystrophy | 1 | 1999 | 147 | 0.160 |
Why?
|
| Hydroxylamines | 1 | 2018 | 40 | 0.160 |
Why?
|
| Diabetic Neuropathies | 1 | 2022 | 410 | 0.160 |
Why?
|
| Humans | 68 | 2023 | 742088 | 0.150 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 1998 | 130 | 0.150 |
Why?
|
| Creatine | 1 | 2019 | 421 | 0.150 |
Why?
|
| Deficiency Diseases | 1 | 2017 | 72 | 0.150 |
Why?
|
| Tarsal Tunnel Syndrome | 1 | 1996 | 9 | 0.150 |
Why?
|
| Paralysis | 1 | 1998 | 249 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3239 | 0.140 |
Why?
|
| Double-Blind Method | 11 | 2021 | 12017 | 0.140 |
Why?
|
| Cryoglobulinemia | 1 | 1996 | 87 | 0.140 |
Why?
|
| Neuromuscular Junction Diseases | 1 | 2015 | 14 | 0.140 |
Why?
|
| Poliomyelitis | 1 | 1997 | 103 | 0.140 |
Why?
|
| Peripheral Nervous System | 1 | 2017 | 150 | 0.140 |
Why?
|
| Muscular Dystrophies | 2 | 2015 | 393 | 0.140 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2020 | 290 | 0.140 |
Why?
|
| 4-Aminopyridine | 1 | 2015 | 81 | 0.130 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 657 | 0.130 |
Why?
|
| Orphan Drug Production | 1 | 2015 | 50 | 0.130 |
Why?
|
| Potassium Channel Blockers | 1 | 2015 | 171 | 0.130 |
Why?
|
| Sciatic Nerve | 1 | 2019 | 609 | 0.130 |
Why?
|
| Middle Aged | 33 | 2021 | 213127 | 0.130 |
Why?
|
| Vital Capacity | 5 | 2019 | 922 | 0.130 |
Why?
|
| Sample Size | 1 | 2018 | 844 | 0.130 |
Why?
|
| Copper | 1 | 2017 | 366 | 0.130 |
Why?
|
| Action Potentials | 3 | 2011 | 1814 | 0.130 |
Why?
|
| Serine | 1 | 2019 | 828 | 0.130 |
Why?
|
| Tamoxifen | 1 | 2019 | 980 | 0.130 |
Why?
|
| Female | 43 | 2023 | 379592 | 0.130 |
Why?
|
| Clozapine | 1 | 1998 | 498 | 0.120 |
Why?
|
| Arthralgia | 1 | 2019 | 456 | 0.120 |
Why?
|
| Spinal Cord Diseases | 1 | 2017 | 299 | 0.120 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2014 | 61 | 0.120 |
Why?
|
| Adult | 33 | 2022 | 213712 | 0.120 |
Why?
|
| Cerebrospinal Fluid | 1 | 2017 | 534 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 1999 | 786 | 0.120 |
Why?
|
| Anti-Asthmatic Agents | 1 | 1998 | 533 | 0.120 |
Why?
|
| Diplopia | 1 | 2015 | 199 | 0.120 |
Why?
|
| Ankle | 1 | 1996 | 327 | 0.110 |
Why?
|
| Zinc | 1 | 2017 | 683 | 0.110 |
Why?
|
| Voice Disorders | 1 | 1996 | 276 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 35342 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 1847 | 0.110 |
Why?
|
| Vasculitis | 1 | 1996 | 521 | 0.110 |
Why?
|
| Spinal Cord | 1 | 2021 | 1807 | 0.110 |
Why?
|
| Ileus | 1 | 2012 | 58 | 0.100 |
Why?
|
| Muscle Strength | 3 | 2021 | 586 | 0.100 |
Why?
|
| Leg | 2 | 2012 | 1110 | 0.100 |
Why?
|
| Sarcoidosis | 1 | 2017 | 503 | 0.100 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 1199 | 0.100 |
Why?
|
| Peripheral Nerves | 2 | 2009 | 474 | 0.100 |
Why?
|
| Neuroprotective Agents | 1 | 2018 | 941 | 0.100 |
Why?
|
| Polysomnography | 1 | 1997 | 1772 | 0.100 |
Why?
|
| Hypoglossal Nerve | 1 | 2011 | 95 | 0.100 |
Why?
|
| Aged | 24 | 2021 | 162944 | 0.100 |
Why?
|
| Skin | 2 | 2015 | 4353 | 0.090 |
Why?
|
| Male | 36 | 2021 | 349538 | 0.090 |
Why?
|
| Disease Progression | 8 | 2020 | 13256 | 0.090 |
Why?
|
| Airway Remodeling | 1 | 2011 | 132 | 0.090 |
Why?
|
| Pain Measurement | 2 | 2019 | 3418 | 0.090 |
Why?
|
| Immunosuppressive Agents | 3 | 2020 | 4147 | 0.090 |
Why?
|
| Anterior Horn Cells | 1 | 2009 | 19 | 0.090 |
Why?
|
| Methotrexate | 1 | 2016 | 1720 | 0.090 |
Why?
|
| History, 21st Century | 1 | 2015 | 1533 | 0.090 |
Why?
|
| Biological Dressings | 1 | 2009 | 30 | 0.090 |
Why?
|
| Biopsy | 3 | 2000 | 6756 | 0.080 |
Why?
|
| Motor Neuron Disease | 1 | 2009 | 106 | 0.080 |
Why?
|
| Photochemistry | 1 | 2009 | 238 | 0.080 |
Why?
|
| Disease Management | 1 | 2019 | 2450 | 0.080 |
Why?
|
| Vaccines | 1 | 1997 | 817 | 0.080 |
Why?
|
| Statistics as Topic | 2 | 2016 | 2372 | 0.080 |
Why?
|
| Central Nervous System Agents | 1 | 2008 | 72 | 0.080 |
Why?
|
| Abdominal Pain | 1 | 2015 | 1059 | 0.080 |
Why?
|
| Valine | 1 | 2009 | 413 | 0.080 |
Why?
|
| Lumbar Vertebrae | 1 | 2017 | 1844 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 17400 | 0.080 |
Why?
|
| Receptors, Cholinergic | 2 | 2020 | 238 | 0.080 |
Why?
|
| Weight Loss | 1 | 2019 | 2604 | 0.080 |
Why?
|
| Amnion | 1 | 2009 | 208 | 0.080 |
Why?
|
| Alanine | 1 | 2009 | 572 | 0.070 |
Why?
|
| Syndrome | 2 | 2009 | 3248 | 0.070 |
Why?
|
| Respiration, Artificial | 3 | 2020 | 2566 | 0.070 |
Why?
|
| Severity of Illness Index | 5 | 2018 | 15530 | 0.070 |
Why?
|
| Treatment Outcome | 9 | 2021 | 62966 | 0.070 |
Why?
|
| Deep Sedation | 1 | 2008 | 121 | 0.070 |
Why?
|
| Respiratory Function Tests | 3 | 2019 | 1613 | 0.070 |
Why?
|
| Chest Wall Oscillation | 1 | 2006 | 12 | 0.070 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2010 | 555 | 0.070 |
Why?
|
| Muscle Strength Dynamometer | 2 | 2018 | 43 | 0.070 |
Why?
|
| Reference Values | 2 | 2010 | 4982 | 0.070 |
Why?
|
| Nerve Fibers | 1 | 2010 | 688 | 0.070 |
Why?
|
| Hepatitis C | 1 | 1996 | 1582 | 0.070 |
Why?
|
| Physical Examination | 1 | 2012 | 1239 | 0.070 |
Why?
|
| Deglutition | 2 | 2022 | 197 | 0.070 |
Why?
|
| Hand Strength | 3 | 2020 | 444 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 7153 | 0.060 |
Why?
|
| GTP-Binding Proteins | 1 | 2009 | 970 | 0.060 |
Why?
|
| Neurogenesis | 1 | 2011 | 829 | 0.060 |
Why?
|
| Quality Improvement | 2 | 2022 | 3738 | 0.060 |
Why?
|
| Mutation | 1 | 2009 | 29717 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2011 | 19862 | 0.060 |
Why?
|
| Antipsychotic Agents | 1 | 1998 | 3058 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2012 | 1359 | 0.060 |
Why?
|
| Melanoma | 1 | 2023 | 5462 | 0.060 |
Why?
|
| Tuberculosis | 1 | 2017 | 1904 | 0.060 |
Why?
|
| Cerebral Cortex | 1 | 2021 | 5705 | 0.060 |
Why?
|
| Phenotype | 2 | 2019 | 16331 | 0.060 |
Why?
|
| Prednisone | 2 | 2021 | 1567 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 1617 | 0.060 |
Why?
|
| Electrophysiology | 2 | 1996 | 1309 | 0.060 |
Why?
|
| Disability Evaluation | 2 | 2011 | 1827 | 0.060 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 57683 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 5724 | 0.060 |
Why?
|
| Nerve Regeneration | 1 | 2009 | 791 | 0.060 |
Why?
|
| Sarcoma | 1 | 1994 | 1895 | 0.050 |
Why?
|
| Barium | 1 | 2022 | 62 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3130 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3236 | 0.050 |
Why?
|
| Fructose | 1 | 2003 | 288 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 2014 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 4187 | 0.050 |
Why?
|
| Breathing Exercises | 1 | 2020 | 53 | 0.050 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2000 | 66 | 0.050 |
Why?
|
| Respiration | 1 | 2006 | 1645 | 0.040 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2022 | 434 | 0.040 |
Why?
|
| Research Design | 2 | 2013 | 5979 | 0.040 |
Why?
|
| Respiratory Aspiration | 1 | 2020 | 81 | 0.040 |
Why?
|
| Retrospective Studies | 9 | 2023 | 77098 | 0.040 |
Why?
|
| Time | 1 | 2021 | 530 | 0.040 |
Why?
|
| Serine C-Palmitoyltransferase | 1 | 2019 | 39 | 0.040 |
Why?
|
| Ulnar Nerve | 1 | 1999 | 109 | 0.040 |
Why?
|
| Median Nerve | 1 | 1999 | 132 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2011 | 1808 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2014 | 4369 | 0.040 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 39004 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 7276 | 0.040 |
Why?
|
| Vitamin E Deficiency | 1 | 2017 | 32 | 0.040 |
Why?
|
| Kidney Tubules | 1 | 2000 | 486 | 0.040 |
Why?
|
| Sphingolipids | 1 | 2019 | 159 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 9274 | 0.040 |
Why?
|
| Physicians | 1 | 2015 | 4554 | 0.040 |
Why?
|
| Young Adult | 7 | 2020 | 56350 | 0.040 |
Why?
|
| Adolescent | 9 | 2019 | 85649 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 363 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1998 | 326 | 0.040 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2017 | 116 | 0.040 |
Why?
|
| Sural Nerve | 1 | 1996 | 112 | 0.040 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2017 | 247 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2019 | 931 | 0.030 |
Why?
|
| Time Factors | 7 | 2012 | 40054 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2019 | 449 | 0.030 |
Why?
|
| Phonetics | 1 | 1996 | 206 | 0.030 |
Why?
|
| Botulinum Toxins | 1 | 1996 | 192 | 0.030 |
Why?
|
| Genotype | 1 | 2009 | 12946 | 0.030 |
Why?
|
| Sensation | 1 | 1996 | 337 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2014 | 156 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2014 | 180 | 0.030 |
Why?
|
| Hand | 1 | 2019 | 882 | 0.030 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2015 | 98 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2014 | 254 | 0.030 |
Why?
|
| Extremities | 1 | 2019 | 865 | 0.030 |
Why?
|
| Activin Receptors, Type II | 1 | 2014 | 127 | 0.030 |
Why?
|
| Patients | 1 | 2020 | 892 | 0.030 |
Why?
|
| Thigh | 1 | 2014 | 247 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 939 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2000 | 1869 | 0.030 |
Why?
|
| Positive-Pressure Respiration | 1 | 1997 | 632 | 0.030 |
Why?
|
| Elbow | 1 | 1993 | 136 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1997 | 1141 | 0.030 |
Why?
|
| Half-Life | 1 | 2014 | 658 | 0.030 |
Why?
|
| Accidental Falls | 1 | 2021 | 1057 | 0.030 |
Why?
|
| Foot | 1 | 1996 | 528 | 0.030 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 1994 | 108 | 0.030 |
Why?
|
| Accidents | 1 | 1993 | 164 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2016 | 585 | 0.030 |
Why?
|
| Infant | 4 | 2003 | 35070 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 11695 | 0.030 |
Why?
|
| Reaction Time | 1 | 1999 | 2092 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 1998 | 2422 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 1996 | 924 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2020 | 1659 | 0.030 |
Why?
|
| Hyperalgesia | 1 | 2016 | 502 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2009 | 7873 | 0.030 |
Why?
|
| Functional Laterality | 1 | 1999 | 2290 | 0.030 |
Why?
|
| Vocal Cords | 1 | 1996 | 528 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 1653 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 1357 | 0.030 |
Why?
|
| Arousal | 1 | 1997 | 1165 | 0.030 |
Why?
|
| Forearm | 1 | 1993 | 407 | 0.020 |
Why?
|
| Triglycerides | 1 | 1999 | 2450 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2021 | 1914 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 7901 | 0.020 |
Why?
|
| Canada | 1 | 2016 | 2061 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 26343 | 0.020 |
Why?
|
| Treatment Failure | 2 | 2008 | 2615 | 0.020 |
Why?
|
| Psychometrics | 1 | 2019 | 2999 | 0.020 |
Why?
|
| Pandemics | 2 | 2020 | 8328 | 0.020 |
Why?
|
| Cholesterol | 1 | 1999 | 2895 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2014 | 2335 | 0.020 |
Why?
|
| Thromboembolism | 2 | 2008 | 983 | 0.020 |
Why?
|
| Organ Size | 1 | 2014 | 2253 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2018 | 10248 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 2271 | 0.020 |
Why?
|
| Gastric Bypass | 1 | 2017 | 812 | 0.020 |
Why?
|
| Peroneal Nerve | 1 | 2009 | 79 | 0.020 |
Why?
|
| ROC Curve | 1 | 2016 | 3528 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2000 | 2896 | 0.020 |
Why?
|
| Quality of Life | 2 | 2006 | 12730 | 0.020 |
Why?
|
| Self Report | 1 | 2019 | 3548 | 0.020 |
Why?
|
| Tongue | 1 | 2011 | 406 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 10943 | 0.020 |
Why?
|
| Demography | 1 | 2013 | 1650 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2016 | 2036 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2008 | 664 | 0.020 |
Why?
|
| Exercise Test | 1 | 2014 | 2075 | 0.020 |
Why?
|
| Adjustment Disorders | 1 | 2006 | 70 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2006 | 6587 | 0.020 |
Why?
|
| Data Collection | 1 | 2015 | 3339 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 1993 | 1472 | 0.020 |
Why?
|
| Tracheostomy | 1 | 2008 | 400 | 0.020 |
Why?
|
| Marriage | 1 | 2006 | 338 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 8077 | 0.010 |
Why?
|
| Cohort Studies | 3 | 2018 | 40450 | 0.010 |
Why?
|
| Life Tables | 1 | 2003 | 370 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2014 | 8436 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1996 | 11363 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 3611 | 0.010 |
Why?
|
| Models, Animal | 1 | 2009 | 2170 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 24913 | 0.010 |
Why?
|
| Sleep | 1 | 1997 | 4604 | 0.010 |
Why?
|
| United States | 2 | 2022 | 69693 | 0.010 |
Why?
|
| Animals | 2 | 2010 | 168561 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 3510 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2003 | 25575 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1999 | 40955 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 1185 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2009 | 2924 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2006 | 2303 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2003 | 1241 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 6534 | 0.010 |
Why?
|
| Survival Rate | 1 | 2012 | 12773 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1998 | 300 | 0.010 |
Why?
|
| Asthma | 1 | 1996 | 5955 | 0.010 |
Why?
|
| Social Support | 1 | 2006 | 2117 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 1998 | 374 | 0.010 |
Why?
|
| Pancuronium | 1 | 1996 | 45 | 0.010 |
Why?
|
| Vecuronium Bromide | 1 | 1996 | 33 | 0.010 |
Why?
|
| Atracurium | 1 | 1996 | 52 | 0.010 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 1996 | 147 | 0.010 |
Why?
|
| Albuterol | 1 | 1996 | 208 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1996 | 388 | 0.010 |
Why?
|
| Child | 2 | 1999 | 77478 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 21719 | 0.010 |
Why?
|
| Bronchodilator Agents | 1 | 1996 | 502 | 0.010 |
Why?
|
| Anxiety | 1 | 2006 | 4279 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1998 | 2633 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2006 | 4229 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 15056 | 0.010 |
Why?
|
| Pedigree | 1 | 1998 | 4646 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 12344 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1996 | 2107 | 0.000 |
Why?
|
| Risk Factors | 2 | 2008 | 72145 | 0.000 |
Why?
|
| Acute Disease | 1 | 1996 | 7141 | 0.000 |
Why?
|
| Incidence | 1 | 1996 | 20928 | 0.000 |
Why?
|